This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AAJ: Patient Safety At Risk With SCOTUS Mutual V. Bartlett

WASHINGTON, March 18, 2013 /PRNewswire-USNewswire/ -- For the third time in a matter of minutes, Karen Bartlett puts drops in her eyes to substitute for the tears she no longer produces. Legally blind, Karen's eyes are a noticeable injury from her Stevens-Johnson syndrome (SJS), a lifetime condition resulting from taking sulindac, a generic drug prescribed for shoulder pain.   

Tomorrow, the U.S. Supreme Court will hear Karen's case about the legal responsibility generic drug manufacturers have for the safety of their drugs.  This case,  Mutual Pharmaceutical v. Bartlett, will decide the responsibility generic makers have in the overall design of the drugs they produce.  Karen's legal team will argue sulindac was unreasonably dangerous compared to similar drugs.  Three lower courts concurred, awarding Karen $21 million in damages for her injuries.  Mutual argues it is only making a copy of the brand drug, and therefore it has no legal responsibility for its design or safety.

"Generics account for eighty percent of all prescription drugs.  All drug manufacturers should be held responsible for the design and safety warnings of their drugs," said American Association for Justice (AAJ) president Mary Alice McLarty.  "Accountability should not be a matter of brand or generic." 

Karen's SJS resulted in her spending months in a burn unit in a medically induced coma, covered in gauze because her skin would stick to any fabric it touched, resulting in over 60 percent of her skin peeling off.  She had 13 eye surgeries, numerous cornea implants, and now has trouble walking as far as out to her own mailbox.  She cannot drive, read, or eat as she once did.  She is lucky to be alive. 

In 2011, the U.S. Supreme Court ruled in Pliva v. Mensing that a generic drug maker has no responsibility to update its warning label with new or undisclosed risks because the drug must follow the brand label.  As a result, courts have dismissed hundreds of cases of patients that have been injured by dangerous generic drugs, including cases involving generic Darvocet, Reglan, Phenergan, and Ambien, citing Mensing.  

"The [U.S. Food and Drug Administration] FDA approves drugs and devices based on the manufacturers' testing, this does not mean the product is safe," added McLarty.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs